Un­der ‘threat’ of fines, No­var­tis sues HHS over drug pric­ing pro­gram

The bio­phar­ma in­dus­try is not tak­ing the threat of even mod­est civ­il mon­e­tary penal­ties light­ly, as No­var­tis last week sued the Biden ad­min­is­tra­tion’s HHS over …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER